Patents Examined by Audrey L Buttice
-
Patent number: 11957716Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 14, 2022Date of Patent: April 16, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
-
Patent number: 11932694Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: April 19, 2018Date of Patent: March 19, 2024Assignee: Bluefin BioMedicine, Inc.Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
-
Patent number: 11919963Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.Type: GrantFiled: August 1, 2022Date of Patent: March 5, 2024Assignee: Inhibrx, Inc.Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Patent number: 11896619Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: January 8, 2021Date of Patent: February 13, 2024Assignee: Massachusetts Institute of TechnologyInventors: Jianzhu Chen, Guozhu Xie
-
Patent number: 11827716Abstract: Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.Type: GrantFiled: November 14, 2022Date of Patent: November 28, 2023Assignee: ARCELLX, INC.Inventors: David Lafleur, Jeffrey S. Swers, Justin Edwards
-
Patent number: 11802159Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein ?-receptor 4 (GFR?4).Type: GrantFiled: September 29, 2020Date of Patent: October 31, 2023Assignees: The Trustees of the University of Pennsylvania, The Scripps Research InstituteInventors: Donald L. Siegel, Vijay Bhoj, Christoph Rader, Rebecca Goydel
-
Patent number: 11773151Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 29, 2021Date of Patent: October 3, 2023Assignee: Akston Biosciences CorporationInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11718657Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: June 19, 2018Date of Patent: August 8, 2023Assignee: Immunocore LimitedInventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
-
Patent number: 11713348Abstract: The present disclosure relates to a scFv amino acid sequence capable of recognizing CD19 antigen and a nucleotide sequence encoding the same, and also relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their uses in the manufacture of a medicament for treating tumors. The chimeric antigen receptor of the present disclosure comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular costimulatory signaling domain, wherein the extracellular domain comprises a CD19 antigen-recognizing and binding domain. The chimeric antigen receptor of the present disclosure has been humanized, resulting in a longer survival period in vivo, and a corresponding extended complete remission period in patients.Type: GrantFiled: March 8, 2019Date of Patent: August 1, 2023Assignee: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE CO., LTDInventors: Peng Li, Ruocong Zhao, Zhaoyang Tang, Le Qin, Yuanbin Cui, Simiao Lin, Yao Yao
-
Patent number: 11685782Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.Type: GrantFiled: October 23, 2018Date of Patent: June 27, 2023Assignees: Children's Medical Center Corporation, President & Fellows of Harvard CollegeInventors: Yang Shi, Wanqiang Sheng, Arlene H. Sharpe, Martin W. LaFleur
-
Patent number: 11673934Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 29, 2021Date of Patent: June 13, 2023Assignee: Akston Biosciences CorporationInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11655297Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.Type: GrantFiled: November 28, 2018Date of Patent: May 23, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
-
Patent number: 11648274Abstract: The present invention provides a chimeric polypeptide comprising: an antigen-binding domain which constitutively binds to an ectodomain of a first chain of a cytokine receptor; a transmembrane domain; and an endodomain from a second chain of the cytokine receptor which chimeric polypeptide, when expressed in a cell, binds to the endogenous first chain of the cytokine receptor causing constitutive cytokine signalling.Type: GrantFiled: November 23, 2018Date of Patent: May 16, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Matteo Righi, Simon Thomas, Shimobi Onuoha, Shaun Cordoba
-
Patent number: 11613581Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).Type: GrantFiled: October 16, 2018Date of Patent: March 28, 2023Assignee: Pfizer, Inc.Inventors: Manoj Baburao Charati, Yoon-Chi Han, Madan Katragadda, Nicole Melissa Piché-Nicholas, Lawrence Nathan Tumey
-
Patent number: 11596655Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for modulating the Natural Cyotoxicity Receptor 2 (NCR2).Type: GrantFiled: April 27, 2018Date of Patent: March 7, 2023Assignee: Washington UniversityInventors: Marco Colonna, Alexander David Barrow
-
Patent number: 11564946Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.Type: GrantFiled: October 31, 2018Date of Patent: January 31, 2023Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Jacob Randolph Garcia, He Li
-
Patent number: 11559549Abstract: Provided herein are methods and compositions useful for treating PDL1 and/or PDL2 positive cancers through adoptive cell transfer of T cells genetically engineered to express a PD1-specific chimeric antigen receptor. Co-stimulatory domains such as Dap 10 may be included to enhance efficacy.Type: GrantFiled: September 26, 2018Date of Patent: January 24, 2023Assignee: LONGWOOD UNIVERSITYInventor: Amorette Barber
-
Patent number: 11534462Abstract: The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.Type: GrantFiled: December 6, 2018Date of Patent: December 27, 2022Assignee: ABCLON INC.Inventors: Jong Seo Lee, Kyu Tae Kim, Bong Kook Ko, Ki Hyun Kim
-
Patent number: 11529425Abstract: Provided is an immunoconjugate useful in inhibiting tumor growth, and a composition and/or protein mixture comprising the immunoconjugate. Also provided are methods for the production of the immunoconjugate, as well as pharmaceutical uses of the immunoconjugate in inhibiting tumor growth, including but not limited to treatment of cancers.Type: GrantFiled: September 6, 2018Date of Patent: December 20, 2022Assignee: Dingfu Biotarget Co., Ltd.Inventors: Ting Xu, Kai Fu, Yan Luan, Xiaojuan Liu, Jianjian Peng
-
Patent number: 11517632Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.Type: GrantFiled: June 20, 2018Date of Patent: December 6, 2022Assignee: NANOMAB TECHNOLOGY LIMITEDInventors: Hong Hoi Ting, Chung Lim Wong, Wenhua Huang